-
Something wrong with this record ?
Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients
MM. Taj, B. Maecker-Kolhoff, R. Ling, S. Bomken, B. Burkhardt, AKS. Chiang, M. Csoka, A. Füreder, S. Haouy, J. Lazic, N. Miakova, V. Minard-Colin, SD. Turner, A. Uyttebroeck, A. Attarbaschi, European Intergroup for Childhood Non-Hodgkin's...
Language English Country Great Britain
Document type Clinical Trial, Journal Article, Multicenter Study
PubMed
33764500
DOI
10.1111/bjh.17398
Knihovny.cz E-resources
- MeSH
- Allografts MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Lymphoproliferative Disorders * drug therapy etiology mortality MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Brain Neoplasms * drug therapy etiology mortality MeSH
- Child, Preschool MeSH
- Disease-Free Survival MeSH
- Rituximab administration & dosage MeSH
- Injections, Spinal MeSH
- Hematopoietic Stem Cell Transplantation adverse effects MeSH
- Organ Transplantation adverse effects MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin's Lymphoma and/or international Berlin-Frankfurt-Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four-year event-free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.
2nd Department of Pediatrics Semmelweis University Budapest Hungary
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Pediatric Hematology and Oncology Hannover Medical School Hannover Germany
Department of Pediatric Hematology and Oncology University Hospital Leuven Leuven Belgium
Department of Pediatric Hematology and Oncology University of Münster Münster Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025641
- 003
- CZ-PrNML
- 005
- 20211026133629.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.17398 $2 doi
- 035 __
- $a (PubMed)33764500
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Taj, Mary M $u Department of Pediatric Hematology and Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK
- 245 10
- $a Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients / $c MM. Taj, B. Maecker-Kolhoff, R. Ling, S. Bomken, B. Burkhardt, AKS. Chiang, M. Csoka, A. Füreder, S. Haouy, J. Lazic, N. Miakova, V. Minard-Colin, SD. Turner, A. Uyttebroeck, A. Attarbaschi, European Intergroup for Childhood Non-Hodgkin's Lymphoma (EICNHL), the international Berlin-Frankfurt-Münster (i-BFM) Study Group
- 520 9_
- $a Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin's Lymphoma and/or international Berlin-Frankfurt-Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four-year event-free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a alografty $7 D064591
- 650 12
- $a nádory mozku $x farmakoterapie $x etiologie $x mortalita $7 D001932
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a spinální injekce $7 D007278
- 650 12
- $a lymfoproliferativní nemoci $x farmakoterapie $x etiologie $x mortalita $7 D008232
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a transplantace orgánů $x škodlivé účinky $7 D016377
- 650 _2
- $a rituximab $x aplikace a dávkování $7 D000069283
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Maecker-Kolhoff, Britta $u Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Ling, Rebecca $u MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
- 700 1_
- $a Bomken, Simon $u Wolfson Childhood Cancer Research Center, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Burkhardt, Birgit $u Department of Pediatric Hematology and Oncology, University of Münster, Münster, Germany
- 700 1_
- $a Chiang, Alan K S $u Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong
- 700 1_
- $a Csoka, Monika $u 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Füreder, Anna $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Haouy, Stéphanie $u Department of Pediatric Hematology and Oncology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
- 700 1_
- $a Lazic, Jelena $u Department of Pediatric Hematology and Oncology, University Children's Hospital, School of Medicine University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Miakova, Natalia $u Department of Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
- 700 1_
- $a Minard-Colin, Veronique $u Department of Pediatric and Adolescent Oncology, INSERM U1015, Gustave-Roussy Université Paris-Sacaly University, Villejuif, France
- 700 1_
- $a Turner, Suzanne D $u Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, UK $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Uyttebroeck, Anne $u Department of Pediatric Hematology and Oncology, University Hospital Leuven, Leuven, Belgium
- 700 1_
- $a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
- 710 2_
- $a European Intergroup for Childhood Non-Hodgkin's Lymphoma (EICNHL), the international Berlin-Frankfurt-Münster (i-BFM) Study Group
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 6 (2021), s. 1178-1184
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33764500 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133635 $b ABA008
- 999 __
- $a ok $b bmc $g 1714613 $s 1146148
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 193 $c 6 $d 1178-1184 $e 20210325 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20211013
